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Summary The majority of human anti-tumour monoclonal antibodies (Mabs) isolated to date have been
disappointing. Firstly, they react or cross react with intracellular cytoskeletal proteins or nuclear antigens and
therefore are of limited value as blood borne agents. They are also generally of the IgM isotype and show
relatively low intrinsic affinity for the primary epitope. Secondly, such Mabs can be generated from normal,
non tumour bearing subjects at a frequency comparable to their production from tumour patients. This latter
observation is true also for common autoantigens such as DNA and IgG since Mabs to these can also be
generated from normal subjects in addition to autoimmune individuals. This article rationalises these
observations in the context of the requirement for clinical use for human Mabs. It discusses the evidence that
there is a potentially useful B cell response to be immortalised, and examines the consequences of the newly
recognised phenomenon of monoclonal antibody multispecificity both on the methodology of their generation
and on their subsequent use as imaging and therapeutic tools.
Human monoclonal antibody technology has taken longer to
establish than the rodent technique. Several comprehensive
reviews have covered the typical technical problems
encountered (Abrams et al., 1986; Kozbor & Roder, 1983;
Kozbor et al., 1986; Roder et al., 1986). However, within the
last two years the majority of the more obvious technical
difficulties have been overcome. It is now possible to
generate substantial numbers (but not yet substantial
quantities) of human Mabs from either a small (20ml)
sample of blood or, in the case of patients undergoing the
appropriate surgery, relevant involved or uninvolved lymph
nodes. Since cancer bearing individuals cannot necessarily be
hyperimmunised against their own tumours, the finding that
the majority of these antibodies have been of the IgM
isotype which is characteristic of the early, immature,
immune response was not unexpected. Typically, such Mabs
have been generated by fusion with rodent or human lines
(Abrams et al., 1986; Kozbor et al., 1986), by transformation
with Epstein Barr virus, or by a combination of both (Roder
et al., 1986). Selection has generally been by the use of
primary tumour, or more frequently tumour cell lines
immobilised on ELISA plates.
More extensive studies on these human Mabs directed
against either primary tumour cells or cell lines in tissue
culture have shown that these are apparently reactive to
intra-cellular antigens (Cote et al., 1986; Campbell et al.,
1986). From a practical point of view, such antigens are of
limited value in targeting for immunoscintigraphic diagnosis
or therapeutic use. On the theoretical side, it is puzzling to
find that not only tumour patients but also normal
individuals apparently carry substantial numbers of anti-
bodies reactive with intracellular proteins or nuclear
components of both normal and malignant cells. If all
individuals carried a permanent protective antibody
population to guard against tumour development, this might
be rationalised. However, there is no obvious sign of a
depletion in affected individuals. In addition, the antigens
involved are all non tumour specific and are routine
'household' skeletal proteins or nuclear antigens found in
many cell types other than tumours. Such Mabs clearly have
very limited utility.
Several questions arise from these observations. (i) Is there
a clinical requirement for useful human Mabs or will rodent
Mabs be sufficient? If so there is no point in persisting with
this apparently fruitless approach. (ii) Do humans mount
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any useful B lymphocyte mediated immune responses to
tumours at all? (iii) If there are human Mabs with real
clinical significance, how can they be isolated independently
from Mabs to intracellular antigens? This article analyses
these questions in the context of currently available evidence.
I. The requirement for human monoclonal antibodies
(i) In identifying the appropriate molecules to usefor
targeting
The rationale for generating human Mabs has been that the
response of a mouse to a human tumour will obviously
reflect the fact that it is foreign to the mouse. The murine
response may be dominated by those antigenic sites which
are non-conserved between human and mouse but which are
not necessarily tumour associated. In contrast, the response
of a patient to his or her autologous tumour is considered to
be much more relevant. Thus in order to identify the correct
antigens for targeting either human or rodent Mabs, an
analysis of the human response is required.
(ii) For repeated use within any particular patient
Current rodent Mabs which have been shown to be of use in
therapy have been generated against molecules which are
present on both normal and malignant cells, but with higher
density on the latter. In general these are ill-defined high
molecular weight antigens with a substantial proportion of
carbohydrate and the Mabs involved have limited effect. The
amount of isotope used in targeting needs therefore to be
considerable (Cobb & Humm, 1986; Baldwin & Byers, 1986)
and it has been suggested that the dose required to eliminate
the tumour entirely is likely to be unacceptably high
(Vaughan et al., 1986). There is still therefore a requirement
for more specific Mabs with a high tumour/normal cell ratio.
In a large proportion of patients an immune response to
the foreign mouse immunoglobulin is generated by the
patient and therefore a second or third application of
antibody is quickly removed from the system before it can
have any beneficial effect (reviewed by Cobb & Humm,
1986).
Tumour cell heterogeneity is particularly important in this
context. It is not uncommon for metastases to present with
altered phenotype due to this phenomenon. Within any
primary tumour, there are cells which are morphologically
diagnosed as malignant and yet unreactive with the test
marker Mab (reviewed by Poste, 1986).
Essentially, the developmental pathway of the tumour may
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alter as the tumour progresses (Figure 1). What presents as
the bulk of the tumour may not reflect the cell types most
active in metastasis or the original activated precursor cells
from which the tumour can regenerate (Poste, 1986; Greaves,
1982). Panels of Mabs have been suggested as a way of
overcoming this problem since these will lead to a more even
distribution of the antibody and its toxic load throughout
the tumour. If an isotope such as 1-131 with a 1-2 mm range
in tissue is employed, there is an increased chance of
destroying the clonogenic cell, not bearing the marker.
If, however, the clonogenic cell is not destroyed in the
initial treatment, even with panels of Mabs, recurrence or
metastasis is likely to occur, possibly carrying a different
phenotype from the original tumour (Poste, 1986). Thus,
repeated application is necessary and human or humanoid
antibodies become desirable.
(iii) Can rejection ofmouse Mabs be avoided by using
antibodyfragments such as Fab?
It has been known for several years that Fab fragments
generated from IgG molecules have a much reduced affinity
for antigen over whole antibody (at least two orders of
magnitude: reviewed by Steward, 1977). In molecular terms,
this can be explained by the fact that if one arm of the
antibody dissociates, there is another nearby to assist
reassociation. With decavalent IgM antibodies the effect is
even more dramatic and the corresponding Fabs have greatly
reduced affinity over whole antibody (Steward, 1977). Thus
a Fab may be expected to be a poor reagent in relation to
whole antibody and this seems to be the case where it has
been tested clinically. The divalent (Fab)2 fragment has
much of the constant region removed and may well prove
superior to whole antibody in resisting rejection. However, at
least 50% of this fragment contains constant region
sequences which carry considerable interspecies variation and
are therefore antigenic and likely to promote a cross-species
response. In the wider immunological literature, this is
clearly the case (as a prosaic example, anti-Fab antiserum
for any species is readily purchased from all major
suppliers). The use of the divalent or monovalent Fab also
extinguishes any possibility of classical immunological
responses such as the complement cascade or Fc receptor
binding being activated.
(iv) Will human Mabs elicit an anti-idiotype response?
It is very difficult indeed to obtain a response to a mouse
monoclonal antibody injected into a mouse, even although
the idiotype is foreign, and substantial amounts of both
antibody and adjuvant are required to achieve this. In
contrast, a mouse Mab injected back into another species
gives a detectable anti-idiotypic response, presumably due to
the highly immunogenic constant region acting as an
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Figure 1 Development of the tumour cell heterogeneity. The
bulk of the excised tumour does not contain the marker for the
clonogenic cell. If the bulk is removed, the tumour can regrow
bearing the previous or new phenotypic markers.
effective carrier for the idiotypic hapten. From such
precedents, rodent Mabs in man are likely to produce both
an anti-isotype and anti-idiotype response but human Mabs
are very much less likely to do so.
Allotypic variations in man do occur and may possibly
provoke a weak immune response in long-term therapy but
these will also be found with chimeric antibodies produced
by gene cloning (see below). They are also limited in
variability and can be taken into account. Classical sero-
therapy indicates that allotypic variation generates no
apparent major problems.
Thus, in principle, human Mabs can be used on a routine
basis with minimal rejection, unlike rodent Mabs. The same,
or a different human Mab (should the tumour change
phenotype), can then be administered on several occasions.
(v) Can human Mabs be made by modifying mouse Mabs?
To overcome the problems outlined above in (ii) (but not (i)
or (iii)), it may be possible to modify the relevant mouse
Mabs by genetic engineering. It is possible to clone the
human constant regions onto the murine variable regions
and thus construct a hybrid antibody which should
experience less rejection than a full rodent antibody (Figure
2) (Sahagan et al., 1986). This approach has still to be tested
clinically and has potential. Caveats lie in the fact that the
framework regions of the Mab will still be identifiably
different, in the fact that low grade anti-idiotypic and anti-
allotypic responses may occur as with human antibodies, and
in the fact that the current rodent antibodies have limited
specificity in a whole body context. The requirement for a
more precisely identifiable target or targets remains evident.
II. Evidence that there is a B cell mediated response to
tumours available to be detected and isolated
(i) Immune responses in normal individuals
Given that human Mabs to tumours can be isolated from
normal people, one can ask whether these are not more
appropriate sources of material. One could suggest that
individuals with tumours may be lacking in the very
population of antibodies which is sought. However, Mabs to
autoantigens can also be generated from normal subjects
without autoimmune disease (Winger et al., 1983; Ghosh &
Campbell, 1987). In the case of viral infections (e.g.
hepatitis) one does not look to individuals who have never
shown symptoms of the illness for serotherapy. In the case
of tumour patients, those most likely to produce a useful
immune response are clearly patients with a sizeable primary
lesion and no evidence of local spread or metastasis.
(ii) Immune responses to tumours in man
With the development of research into oncogenes it is
becoming clear that by far the majority of oncogene
products are intracellular and highly conserved. The prime
example is the H-ras system where there is one amino acid
different at position 12 which alters the function of a cellular
G-protein. The majority of oncogenes seem to activate or
simulate intracellular proteins (see Darnell et al., 1987). Thus
one could conclude that malignant cells may present to the
body as normal cells and there is no further point in looking
for tumour specific human Mabs.
However, in terms of diagnosis and therapy, differen-
tiation associated cell surface antigens may be valuable
targets for progressive disease. The most obvious of these is
B cell lymphoma where the idiotype (variable region) of the
antibody provides an obvious target. Apart from a single
case (Miller et al., 1982), immunotherapy with rodent Mabs
has been ineffective even with lymphomas. This is almost
certainly due to tumour heterogeneity (see above).
In the case of the common epithelial tumours of man
(colon, lung, breast, prostate), there is no observable increase
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Figure 2 Methods for the construction ofchimaeric mouse-human antibodies.
in the incidence among immunosuppressed patients (see e.g.
Roitt et al., 1985). For example, patients with AIDS do not
display such tumours but rather obscure neoplasms such as
Kaposi's sarcoma or lymphoid tumours. There is therefore
no clear clinical evidence from such patients that there is
indeed an immune response available to be harnessed and
immortalised.
However, AIDS or any form of chronic immuno-
suppression suddenly experienced in adult life, reflects an
abnormal situation. Tumours caused by large DNA viruses
such as CMV (implicated in Kaposi's sarcoma) or EBV
(Burkitt's lymphoma) are thought to be latent in most of this
population. In the case of these large DNA viruses, viral
antigens (although not necessarily oncogene products) might
generate specific cell surface targets for the immune system
and are kept under continuous control. Tumours caused by
such viruses, being present already in such a high proportion
of the population would naturally emerge first in immuno-
suppressed patients who, because of these or other oppor-
tunistic infections which occur in AIDS, are unlikely to
survive for a long enough period of time to present with
epithelial tumours which have a different aetiology. The
differential response to such tumours, as opposed to the
common epithelial tumours of man, has been well reviewed
and analysed (Klein & Klein, 1985).
III. Why are all the human monoclonal antibodies isolated to
date of no apparent utility to the patient from which they
were isolated?
(i) Could antibodies to intracellular antigens have been
generated by cell death releasing unusual amounts ofsuch
antigens?
It is possible to argue that such autoantibodies are generated
in response to the accelerated release of common intra-
cellular antigens from necrotic cells. However, only the
centres of very large tumours tend to be necrotic and, as this
is due to the loss of their blood supply, they are less likely to
stimulate an immune response. Cell death in general is a
regular occurrence in most tissues. In addition, human
monoclonal antibodies to intracellular antigens can be
produced at comparable frequency from normal, non-
tumour bearing individuals. The nature of the identified
autoantigens also mitigates against such an argument. Even
as intracellular antigens, they are not specific to the tumour
type involved but are molecules with
specificity as discussed above.
little cell or tumour
(ii) Have human anti-tumour Mabs been wrongly identified
due to defective methodology?
The true answer to this question is almost certainly that
the past technology of human Mab selection has been
defective. The essential paradox, as discussed above, has
been that from any healthy individual of either sex, it is
possible to produce Mabs to any primary human tumour
and also to DNA, IgG, thyroglobulin and other common
autoantigens. In the autoimmune field, this concept was
naturally recognised earlier and the technology is being
appropriately adapted.
Monoclonal antibodies, particularly but not exclusively
those of the multivalent IgM class, can frequently be shown
to be multispecific (Figure 3) (Ghosh & Campbell, 1986).
Where one or both antigens has a densely packed highly
repeating structure, it is possible for an antibody with very
low intrinsic affinity to bind quite strongly (i.e. the
interaction may represent a minor ionic or hydrophobic
attraction involving only one or two amino acids in the
variable region). There is then much reserve capacity in the
antibody binding site to bind to a second or third antigen
utilising different amino acid residues. Multispecific
monoclonal antibodies typically have molecules with a highly
repeating structure such as DNA, bacterial LPS, or cyto-
skeletal proteins including actin, myosin, cytokeratins and
vimentin as one of the cross reactive antigens. It is
immediately evident that most of the human Mabs isolated
to date fall into this category. The rationalisation of these
antibodies then becomes possible. The patient (or normal
individual) makes routine B cell immune responses to
unidentified environmental antigens. These antibodies are
then effectively 'highjacked' by the monoclonal technologist
who assays them on an ELISA plate under highly artificial
laboratory conditions. It is almost impossible to put cells
onto an ELISA plate leaving every single one intact without
a slight breach in the membrane. The antibody diffuses into
the cells and binds to the highly repeating structures giving a
positive reading and is therefore thought to be tumour
reactive. In the tumour patient (or normal individual), it had
been generated to react with a completely different antigen.
As a consequence of this, most human anti-tumour Mabs
isolated to date are irrelevant reagents. In retrospect, the
ease of production of such Mabs should perhaps have712 M. CAMPBELL et al.
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Figure 3 How a multispecific monoclonal antibody may be wrongly identified as tumour reactive. Note that antibody
multivalence, not shown, further contributes to the effect.
alerted suspicions at an earlier stage. It is quite possible to
generate more than 30 of these antibodies from a small 20ml
sample of blood from any individual and this would have
implied an unexpectedly strong immune response in both
patients and normal individuals.
(iii) Do we yet know ifhumans mount an effective B
lymphocyte response to tumours?
Effectively then, the problem of generating relevant human
monoclonal antibodies has gone full circle. We still do not
know if humans mount an effective B cell response to their
tumours and whether this response can be immortalised by
human monoclonal technology. It is however, possible to
find out. In the first place, the cells which secrete the
infrequent IgG subclasses must be isolated and cloned since
these are rarely multispecific. With humans, this is not easy
since patients obviously cannot be hyperimmunised, but
technically feasible nonetheless if the appropriate selection
techniques are used (Campbell, 1984). It is both relevant and
interesting to note that in the autoimmune field where
similar identification problems have been encountered, (Eilat,
1986; Ghosh & Campbell, 1987) particularly where DNA is
the antigen, it is the IgG class of autoantibody that is found
only in diseased subjects while the IgM can be found in all
individuals (Stollar et al., 1986). Thus, by analogy, it is the
IgG class that should be sought in tumour patients. In the
second place, selection of the appropriate specificities has to
be in such a way that antibodies reactive with intracellular
antigens are not wrongly identified. For example, precise
immunofluorescence methods using intact, viable cells may
be employed. Finally, since this approach is unlikely to give
the unexpectedly high yield of positive reactions which were
observed with the 'highjacked' IgMs to intracellular antigens,
it would be advisable to use the tissue which is most likely to
contain the appropriate lymphocytes, i.e. lymph nodes
draining the tumour bearing area (Section II(i)). Only then
can the true human B cell response to tumours be assessed.
(iv) Has experience with the generation ofhuman Mabs any
relevancefor the generation ofrodent Mabs?
The general phenomenon of highly repetitive antigens
leading to the production of cross-reactive antibodies also
has consequences for the generation of rodent Mabs. Nearly
all of the monoclonal antibodies employed in current
therapy have been of the IgG isotype which has greatly
reduced cross-reactivity with non-identical antigens in
comparison to IgM Mabs (Ghosh & Campbell, 1986b). Such
Mabs give comparatively poor localisation and high
background in irrelevant tissue and this is not surprising
when the antigens concerned are considered. Many of these
are generated to repetitive structures and are likely therefore
to have considerable cross-reactive potential with other
components of the whole human body, say, collagen or
basement membrane. Mabs are always tested against likely
cross-reactive antigens, but it is impossible to test them
against all possible non-identical antigens. This may well
explain why, of two Mabs with apparently similar specificity
profile, one will target with a totally different tissue distri-
bution to the other in vivo. It is relevant to point out that, if
these ill-characterised structures are indeed tumour-
associated, a panel of rodent Mabs to them will be very
much more effective, since each Mab is likely to cross react
with a different irrelevant antigen and whole body imaging
should be much improved. Indeed, it is this polyclonal
reaction which may be the response generated by the normal
human immune system.
Conclusion
The effective use of Mabs for either or both imaging and
therapy of tumours requires a library, each element of which
is monospecific for a cell surface epitope. This library should
not elicit an adverse heterologous response and should
therefore be human or humanoid. Currently available human
Mabs (IgMs) generated from patients are all demonstrably
polyspecific and act against common features of normal cells
due to technical defects in identification. The existence of a
human B cell response to tumours remains to be established
but analogy with human autoimmune systems suggests that
it will lie in the more mature IgG secreting B cell population.
Current assay systems are not designed to detect this
response because the extent of monoclonal antibody multi-
specificity has not been fully appreciated.
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